Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 14;15(1):556.
doi: 10.1007/s12672-024-01433-y.

AURKA inhibition shows promise as a therapeutic strategy for ARID1A-mutant colorectal cancer

Rong-Sheng Qin  1 , Chun-Tao Li  2 , Fei Chen  1 , Shu Luo  1 , Chao Wang  1 , Jie Li  3 , Shan Xu  4   5 , MingWei Kang  6 , Hao-Wen Hu  7
Affiliations

AURKA inhibition shows promise as a therapeutic strategy for ARID1A-mutant colorectal cancer

Rong-Sheng Qin et al. Discov Oncol. .

Abstract

Purpose: Mutations in ARID1A frequently occur in colorectal cancer (CRC) cells. However, there are currently no clinical treatment options specifically addressing this aberration. The preliminary in vitro experiments revealed a synthetic lethal interaction between ARID1A and Aurora kinase A (AURKA) in colorectal cancer (CRC) cells.

Methods: We collected samples from 80 CRC patients and evaluated the efficacy of AURKA inhibitor (AURKAi) using the ATP-tumor chemosensitivity assay (ATP-TCA) on untreated ARID1A-proficient (ARID1A +) and ARID1A-deficient (ARID1A-) CRC patient samples. In addition, we validated this result by a clonogenic assay. Additionally, we examined the effects of AURKA inhibitors on cell cycle progression and apoptosis in ARID1A + and ARID1A- CRC patient samples using flow cytometry.

Results: The results showed that AURKAi selectively inhibited the growth of ARID1A- CRC cells. Furthermore, AURKA inhibitors significantly increased G2/M arrest and induced apoptosis in ARID1A- cells.

Conclusion: We believe that AURKAi hold promise as potential therapeutics for ARID1A mutation colorectal cancer patients.

Keywords: ARID1A; AURKA; Colorectal cancer; Ex vivo; SWI/SNF.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Effect of AURKAi in CRC patients’ samples. A: illustration of immunohistochemistry (IHC) results showing the presence or absence of ARID1A expression in CRC clinical tumor. B: evaluation of the impact of the AURKAi alisertib on ex vivo CRC patient cells using the ATP-Tumor Chemosensitivity Assay. The assay measured ATP activity in ex vivo cells treated with alisertib at concentrations ranging from 0 to 10 nM in CRC patient cells with ( +) and without (-) ARID1A expression. X-axis is the test drug concentration percentage, and the Y-axis is the tumor growth inhibition percentage. C: results of the colony formation assay of ARID1A + and ARID1A—Ex Vivo CRC cells in 20 nM alisertib; D: percentage of colonies formed of ARID1A + and ARID1A—Ex Vivo CRC cells in 20 nM alisertib. E: results of the colony formation assay of ARID1A + and ARID1A—Ex Vivo CRC cells in 35 nM alisertib; F: percentage of colonies formed of ARID1A + and ARID1A—Ex Vivo CRC cells in 35 nM alisertib
Fig. 2
Fig. 2
Effects of AURKAi on Cell Cycle Arrest and apoptosis in ARID1A- CRC patients’ samples. A: effect of AURKAi on cell cycle progression; B: effect of AURKAi on apoptosis
See this image and copyright information in PMC

References

    1. Mathur R, Alver BH, San Roman AK, Wilson BG, Wang X, Agoston AT, Park PJ, Shivdasani RA, Roberts CW. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. Nat Genet. 2017;49(2):296–302. - DOI - PMC - PubMed
    1. Mittal P, Roberts CW. The SWI/SNF complex in cancer—biology, biomarkers and therapy. Nat Rev Clin Oncol. 2020;17(7):435–48. - DOI - PMC - PubMed
    1. Wu R-C, Wang T-L, Shih I-M. The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther. 2014;15(6):655–64. - DOI - PMC - PubMed
    1. Xu S, Sak A, Niedermaier B, Erol YB, Groneberg M, Mladenov E, Kang M, Iliakis G, Stuschke M. Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy. Front Oncol. 2022;12: 999626. - DOI - PMC - PubMed
    1. Wang J, Yan H-B, Zhang Q, Liu W-Y, Jiang Y-H, Peng G, Wu F-Z, Liu X, Yang P-Y, Liu F. Enhancement of E-cadherin expression and processing and driving of cancer cell metastasis by ARID1A deficiency. Oncogene. 2021;40(36):5468–81. - DOI - PubMed

LinkOut - more resources